Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-140882

Published: 2020

Journal Articles

Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq

Blood (2019) 134 (Supplement_1): 5217.

https://doi.org/10.1182/blood-2019-129134

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Shaum M Kabadi, PhD MPH, Ravi K Goyal, MS, Saurabh P Nagar, MS, Keith L Davis, MA, Hannah Le, PharmD, MPH, Xianglin L Du, MB, MS, PhD, Preetesh Jain, MBBS,MDDM,PhD, Michael L. Wang, MD, Jorge Enrique Romaguera, MD, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 63.

https://doi.org/10.1182/blood-2019-122841

Published: 2019

Journal Articles

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Blood (2019) 134 (Supplement_1): 2815.

https://doi.org/10.1182/blood-2019-126175

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Blood (2019) 134 (Supplement_1): 3988.

https://doi.org/10.1182/blood-2019-125800

Published: 2019

Journal Articles

Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients

Blood (2019) 134 (Supplement_1): 1526.

https://doi.org/10.1182/blood-2019-125936

Published: 2019

Journal Articles

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib

Preetesh Jain, MBBS, MDDM, PhD, Rashmi Kanagal-Shamanna, MD, Shaojun Zhang, PhD, Chi Young Ok, MD, Makhdum Ahmed, MD PhD MPH, Diana Nava, Maria Badillo, Krystle Nomie, PhD, Keyur Patel, MD PhD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Luis Fayad, MD, Loretta J. Nastoupil, MD, L. Jeffrey Medeiros, MD, Sattva S. Neelapu, MD, Jorge Enrique Romaguera, Nathan H. Fowler, MD, Linghua Wang, PhD, Michael Wang, MD

Blood (2018) 132 (Supplement 1): 4151.

https://doi.org/10.1182/blood-2018-99-115179

Published: 2018

Journal Articles

Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic ( dn MCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients

Blood (2018) 132 (Supplement 1): 1599.

https://doi.org/10.1182/blood-2018-99-115360

Published: 2018

Journal Articles

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients

Preetesh Jain, MBBS,MDDM,PhD, Loretta J. Nastoupil, MD, Rashmi Kanagal-Shamanna, MD, Graciela M. Nogueras González, MPH, Mansoor Noorani, Jorge Enrique Romaguera, Luis Fayad, MD, Felipe Samaniego, MD, Jason R. Westin, MD, L. Jeffrey Medeiros, MD, Sattva Neelapu, Michael Wang, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 1600.

https://doi.org/10.1182/blood-2018-99-118489

Published: 2018

Journal Articles

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Jorge Enrique Romaguera, Hun Ju Lee, MD, Rohinton Tarapore, PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Joshua E. Allen, PhD, Lee Schalop, MD, Andrew Zloza, MD, Chi Young Ok, MD, Maria Badillo, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 5163.

https://doi.org/10.1182/blood.V130.Suppl_1.5163.5163

Published: 2017

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

Paolo Strati, MD, Jorge Enrique Romaguera, MD, Larry W. Kwak, MD, PhD, Fredrick B Hagemeister, MD, Maria Alma Rodriguez, MD, Yasuhiro Oki, MD, Jason R. Westin, MD, Francesco Turturro, MD, Michael J. Overman, MD, Sattva S. Neelapu, MD, Nathan Fowler, MD, Luis Fayad, MD

Blood (2013) 122 (21): 3028.

https://doi.org/10.1182/blood.V122.21.3028.3028

Published: 2013

Journal Articles

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.

Felipe Samaniego, MD, MPH, Jillian F Wise, BS, Rong-Hua Tao, MD, PhD, Haifeng Zhu, PhD, Xue Ao, MS, Zeming Chen, PhD, Wenzhuo Zhuang, PhD, Frank K Braun, PhD, Rohit Mathur, PhD, Jorge Enrique Romaguera, MD, Luis Fayad, MD, Michael Wang, MD, Peter McLaughlin, MD, Timothy J. McDonnell, MD, PhD, Keyur P. Patel, MD, PhD, Sattva S. Neelapu, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD

Blood (2012) 120 (21): 2406.

https://doi.org/10.1182/blood.V120.21.2406.2406

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.

Blood (2006) 108 (11): 2749.

https://doi.org/10.1182/blood.V108.11.2749.2749

Published: 2006

Journal Articles

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Yasuhiro Oki, MD, Barbara Pro, MD, Jorge Enrique Romaguera, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Donald Podoloff, MD, Barry Samuels, MD, Evelyne Loyer, MD, Yuhong Zhou, MD, Anas Younes, MD

Blood (2006) 108 (11): 2714.

https://doi.org/10.1182/blood.V108.11.2714.2714

Published: 2006

Journal Articles

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Shyam Teegala, MD, Xiao Zhou, MD, PhD, Auris Huen, PHARMD, Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 4103.

https://doi.org/10.1182/blood.V108.11.4103.4103

Published: 2006

Journal Articles

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Auris Huen, PharmD, Xiao Zhou, MD, PhD, Shyam Teegala, M.D., Yuan Ji, PhD, Luis Fayad, M.D., Jorge Enrique Romaguera, M.D., F.B. Hagemeister, M.D., Saroj Vadhan-Raj, M.D.

Blood (2006) 108 (11): 3994.

https://doi.org/10.1182/blood.V108.11.3994.3994

Published: 2006

NARROW

Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma

Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients

Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib

Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic ( dn MCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients

Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of 172 Patients

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin.

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors.

Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only